WASHINGTON, Sept. 25 (UPI) -- With approval from the FDA now secured, Blaze Bioscience, a young biotech company, will move forward with its plans to inject 21 cancer patients with so-called Tumor Paint -- a cancer cell-targeting compound derived from the venom of deathstalker scorpions.
Tumor Paint doesn't cure cancer, nor does it intend to. But it's creators believe it can help surgeons more completely eradicate malignant tumors by finding and highlighting all the cancerous cells in a person's body. And by highlighting, researchers really do mean highlighting -- glowing bright green.